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hould We Routinely Use
rug-Eluting Stents for Acute
yocardial Infarction?
et’s Wait and See*
indy L. Grines, MD, FACC,
ames A. Goldstein, MD, FACC,
obert D. Safian, MD, FACC
oyal Oak, Michigan
ow quickly time flies! It has now been a decade since
eporting the first randomized trial of coronary stenting for
cute myocardial infarction (AMI). At that time, it was
hocking to think that one could place a metal foreign body
nto a thrombogenic milieu and expect the artery to remain
atent. Hence, we and others conducted several randomized
rials comparing primary angioplasty and stenting, and
arefully excluded lesions at high risk of thrombosis (large
hrombus, no reflow), utilized stents with heparin coatings
1), and optimized the antithrombotic strategy (2). These 13
andomized AMI trials showed that compared with percu-
aneous transluminal coronary angioplasty for AMI, bare-
etal stents (BMS) reduced restenosis and target vessel
evascularization (TVR) but did not improve mortality (3)
r ventricular function (1,2). Based on improved angio-
raphic results and reductions in acute and long-term
schemia, BMS quickly became the standard of care for
MI patients.
See page 129
When drug-eluting stents (DES) became available, they
ere widely applied in a variety of off-label indications,
ncluding AMI. Although clinical outcomes after off-label
se of BMS and DES were generally less favorable than for
n-label indications (4,5), 60% of stents were placed for
ff-label indications. Nevertheless, compared with BMS,
ES were associated with less TVR and rates of death and
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harmaceuticals.yocardial infarction that were similar to or better than
MS (6–11).
So why are we concerned about DES in the setting of
MI? First, there may be less benefit in AMI patients.
cute lesions may have more thrombus and less fibrous
theroma and may be less prone to restenosis (compared
ith stable plaques). Second, recurrent angina is infrequent
n post-myocardial infarction patients and ischemia-driven
VR is low (5% to 8%) after BMS (1,2). Third, DES may
e potentially harmful. After reperfusion, the coronary
rtery may remain underperfused or compressed from myo-
ardial edema or abnormal vasomotor tone. Difficulty in
etermining the correct vessel size may result in late stent
alapposition, an important contributor to late stent
hrombosis. Moreover, clinical presentation with acute cor-
nary syndrome, intracoronary thrombus, low cardiac out-
ut, hypotension, and hypercoagulable states—all common
uring acute myocardial infarction—are strong predictors of
ES thrombosis (12–15). The underlying unstable plaque
ubstrate of thin fibrous cap and necrotic atherosclerotic
ore may further contribute to delays in stent endotheliali-
ation and subsequent thrombosis. Finally, premature dis-
ontinuation of antiplatelet therapy is of particular concern
16) because medication compliance may be poor after
MI. In fact, one prospective AMI registry (17) found that
4% of patients treated with DES had stopped clopidogrel
ithin the first month. Clearly these issues are concerning
o the interventional cardiologist.
Theoretical concerns aside, how well are DES perform-
ng in AMI? In this issue of JACC: Cardiovascular Interven-
ions, Hannann et al. (18) reported their observations from
he New York State PCI Registry. Over a 15-month
nterval between October 2003 and December 2004, the
egistry enrolled 1,926 patients who were treated with stents
ithin 12 h of symptom onset of ST-segment elevation
yocardial infarction (STEMI). Surprisingly, patients
reated with DES had lower mortality and need for subse-
uent bypass surgery even after adjusting for baseline
ifferences. As in all registries, important anatomical and
linical variables may have resulted in physician selection
ias. For example, DES may have been avoided in patients
onsidered for subsequent coronary artery bypass graft,
iven the surgeon’s reluctance to operate on patients taking
lopidogrel. Such selection bias may account for the ob-
erved reduction in coronary artery bypass graft after DES,
hereas overall TVR was similar between DES and BMS.
ikewise, differences in mortality may be caused by selection
ias or chance, because randomized trials have not shown a
ortality advantage of DES over BMS (19). Finally, stent
hrombosis and reinfarction rates were not measured, events
ere not monitored or adjudicated, and antiplatelet use is
nknown. Despite these deficiencies, the topic is very
elevant to clinical practice and the suggested safety of DES
n STEMI patients is reassuring.
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137In contrast, other registries have not shown improvement
n major adverse cardiac events when DES is used in
TEMI patients (20). In fact, a large European registry
uggested that DES are harmful (21). Given the high cost
f DES, the GRACE (Global Registry of Acute Coronary
vents) investigators speculated that operators may be
nlikely to use DES in STEMI patients with a high risk of
ortality, and this may account for the low death rate
bserved in some registries. Accordingly, they performed an
nalysis excluding STEMI patients who died during the
nitial hospitalization. Survival after DES and BMS began
o diverge at 6 months, and by 2 years patients who received
ES had a 4-fold increase in the risk of death compared
ith BMS (21). Some have speculated that a late increase in
ortality may be caused by withdrawal of dual antiplatelet
herapy when DES are not fully endothelialized. However,
ortality differences between DES and BMS have not been
bserved in other large stent registries, so interpretation of
hese conflicting results remains difficult.
Randomized controlled trials are the most precise method
f determining the risk and benefit of different treatments.
ccordingly, Kastrati et al. (22) published a meta-analysis of
 randomized trials comparing DES with BMS in 2,786
TEMI patients. The DES significantly reduced the need
or re-intervention compared with BMS (5.0% to 13.3%,
azard ratio 0.38, 95% confidence interval 0.29 to 0.50, p 
.001). During follow-up ranging from 1 to 2 years, death
ccurred in 4.6% and reinfarction occurred in 3.5%, but
here were no differences in stent thrombosis, myocardial
nfarction, or death between DES or BMS. As better
utcomes are often observed in randomized trials compared
ith registries because of careful patient and lesion selection
nd improved medication compliance, it is uncertain
hether these findings are applicable to a broad STEMI
opulation of higher-risk patients and complex lesions.
One disturbing phenomenon is an apparent increase in
ubacute stent thrombosis in STEMI patients compared
ith several years ago. The 30-day risk of BMS thrombosis
as 0 to 1% in Stent PAMI (Primary Angioplasty in
yocardial Infarction) (1) and CADILLAC (Controlled
bciximab and Device Investigation to Lower Late Angio-
lasty Complications) (2). In contrast, the current rate of
0-day BMS and DES thrombosis is 1.5% to 2.0% (22,23).
he higher contemporary rates of stent thrombosis may be
ttributable to slight differences in definitions, use of stents
n lesions with a high risk of stent thrombosis, or failure to
dhere to established recommendations for antithrombotic
herapies) (2,24).
Clearly, additional data are required before making firm
ecommendations regarding indications and contraindica-
ions for DES in AMI. The HORIZONS (Harmonizing
utcomes with Revascularization and Stents) trial has
andomized 2,500 STEMI patients to Taxus DES versus
MS, with 1-year follow-up anticipated by the fall of 2008.
1owever, even these results may be questioned because of
otential differences in restenosis and stent thrombosis rates
ith paclitaxel-eluting stents and sirolimus-eluting stents
19). Moreover, the low adverse event rate within 12
onths of primary PCI may limit our ability to detect
ifferences in subacute stent thrombosis and mortality.
herefore, until longer-term followup is available for all
ypes of DES, we believe that the appropriateness of DES
or STEMI will be hotly debated for years to come.
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